Daiwa Securities Group Inc. Acquires 1,278 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Daiwa Securities Group Inc. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,662 shares of the biopharmaceutical company's stock after buying an additional 1,278 shares during the quarter. Daiwa Securities Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $15,430,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $39,000. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $28,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $49,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the subject of a number of recent analyst reports. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 price objective for the company. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $973.13.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $26.67 during midday trading on Tuesday, reaching $718.16. The stock had a trading volume of 1,108,039 shares, compared to its average volume of 620,338. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The firm's 50-day moving average price is $697.08 and its 200 day moving average price is $842.19. The firm has a market capitalization of $78.51 billion, a PE ratio of 18.76, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $11.86 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.